



Sustainability at Aescap

Since its inception, Aescap has taken environmental, social and governance (ESG) factors into consideration by analyzing sustainability impact of its portfolio companies and potential new investments. By continuously doing so, Aescap aims to encourage companies in our sector to act with the well-being of people and our planet in mind. The fund focuses its investments in companies developing treatments that are aimed to significantly improve the life of patients and benefit society as a whole.

What is ESG?

ESG factors are extra-financial factors that can influence, and be influenced by, our business activities. If not addressed appropriately they can escalate into substantial risks.

Examples of ESG risks include human rights violations, over the top medicine pricing, or severe corruption allegations. We diligently manage ESG risks to ensure they do not develop or materialize.

On the other hand, ESG factors can also present opportunities to induce positive change, such as increased requirements for environmental investments or offering solutions to improve social welfare, for instance through better access to medicine.

ESG at Aescap

The approach to ESG factors at Aescap is twofold. Firstly, sustainability risks are monitored following the Materiality Map by the Sustainability Accounting Standards Board (SASB) to define ESG risks considered to be material in the Life Sciences sector. Secondly, Aescap promotes social characteristics in line with the Article 8 of the EU Sustainable Finance Disclosure Regulation (SFDR). Both approaches are outlined in more detail below.

Sustainability risks

Considering the sector focus of the fund, the following sustainability risks have been identified to be likely material for the investments made by Aescap in the economic sector Biotechnology & Pharmaceuticals:

- Safety and quality of clinical trials and participants
- Access to medicine, affordability & pricing
- Medicine safety, defects, inadequate disclosure of risks during pre-clinical studies and clinical trials
- Patient follow-up and support for marketed products and during clinical trials
- Ethical marketing to medical specialists and patients
- Employee engagement, diversity & inclusion
- Quality and safety of supply chain management
- Excessive pricing and uncompetitive behavior

These risks are monitored on a continuous basis through engagement with portfolio companies as well as analyses of data either publicly available or provided to the fund. Material changes to the individual sustainability risks of an investment are not expected to occur often.

Measurement of social characteristics

The investments of the fund are contributing to the development, manufacturing and distribution of medicines worldwide. Aescap invests in companies developing innovative treatments, often for diseases without any treatment available so far. It also champions best practices in the sector through engagement with the management of companies. The Fund reports annually on the following:

- Percentage of investee companies researching, developing or producing treatment for diseases with a high unmet medical need
- Percentage of investee companies researching, developing or producing treatment for rare diseases
- Progress on ESG best-practice engagement following a sustainable investment strategy

In addition to the above, Aescap monitors the alignment of portfolio companies and potential new investments with social characteristics based on the exclusion, inclusion and engagement criteria below.

| Exclusions | Inclusions | Engagement |
|--|---|---|
| <p>Inclinations of</p> <ul style="list-style-type: none"> • Not complying with EEA or EPA regulations on waste management • Weak business ethics and competitive behavior • Excessive price setting • Poor disclosure and mislabeling • Unnecessary animal testing | <p>Strong policies on</p> <ul style="list-style-type: none"> • Patient health and safety • Product quality and safety • Affordable access to medicine • Stakeholder engagement • Employee engagement and diversity • Marketing and ethical advertising | <p>Maximum three year</p> <ul style="list-style-type: none"> • Engagement with companies where the sustainability risk analysis or good governance screening indicates below average preparedness |

Contact

For more information on ESG at Aescap, please do not hesitate to contact Patricia Allam (IR) via pallam@aescap.com or +316 111 855 96

Kind regards,

The Aescap Team

About Aescap Life Sciences

Aescap Life Sciences is an open-end fund investing in public biotech companies that develop and market next generation medical treatments. Within its focused portfolio of around 20 companies it diversifies over different diseases, development phases and geographies. Companies are selected for their growth potential ('earning power') and limited risk (technological and financial). Investors can enter and exit the fund twice per month.

The selection of companies in our portfolio is based on 'high conviction' - extensive fundamental analyses combined with intense interaction with management and relevant experts. The fund's performance is fueled by stock picking and an active buy and sell discipline. Biotech stocks are known for their very low correlation and high volatility, caused by media, macro-events and short-term speculative investors. This creates an ideal setting for a high conviction fund manager to invest in undervalued companies with a great mid- and long-term earning power. The fund has an average annual net performance target of 20% over the mid-term (4-5 years)

5-star Morningstar rating:

Morningstar has rated Aescap Life Sciences as a 5-star investment fund, the highest possible rating given. Morningstar's rating has become the industry's leading standard for determining a fund's performance (risk/reward) relative to other funds. To rate a fund, Morningstar takes into account the long-term performance (3+ years) and only the top 10% best performing funds will receive a 5-star rating.



TM

Disclaimer:

Do not run any unnecessary risk. Read the Key Information Document and the Key Investor Information Document (the Key Investor Information Document is available for the Aescap Life Sciences Investors and the Aescap Life Sciences Investors Class <500k only). This communication is neither an offer to sell nor a solicitation to invest. Past performance is not indicative of future results. The value of investments and any income generated may go down as well as up and is not guaranteed. Privium Fund Management B.V. (Privium) is authorized and regulated by the Dutch Authority for the Financial Markets (www.afm.nl) as an Alternative Investment Fund Manager (AIFM). The Fund and its manager, Privium Fund Management B.V., are held in the register of Dutch Authority for the Financial Markets. The Prospectus of the Fund, the Key Information Document and the Key Investor Information Document can be downloaded via the website of the Fund (www.aescap.com) and the Fund Manager (www.priviumfund.com). The performance overviews shown in this communication have been carefully composed by Privium Fund Management B.V. No rights can be derived from this communication.

Disclosures for Swiss Investors:

The Fund has appointed ACOLIN Fund Services AG, succursale Genève, 6 Cours de Rive, 1204 Geneva, Switzerland, as its Swiss Representative. Banque Heritage SA, 61 Route de Chêne, CH-1207 Geneva, Switzerland is the Swiss Paying Agent. In Switzerland shares of Aescap Life Sciences shall be distributed exclusively to qualified investors. The fund offering documents and audited financial statements can be obtained free of charge from the Representative. The place of performance with respect to the shares of Aescap Life Sciences distributed in or from Switzerland is the registered office of the Representative.

Aescap • Barbara Strozzilaan 101, 1083 HN, Amsterdam, The Netherlands

Tel. +31 20 570 29 40 • E-mail: service@aescap.com

